MLKL Polymerization-Induced Lysosomal Membrane Permeabilization Drives Necroptosis via Cathepsin B

Study Background and Research Question

Necroptosis is a regulated, lytic form of cell death characterized by organelle swelling, plasma membrane rupture, and the release of intracellular danger signals. This process has been implicated in a range of human diseases spanning inflammation, infection, tissue injury, and malignancy. A canonical necroptosis pathway involves the activation of receptor-interacting protein kinases (RIPK1 and RIPK3) and mixed lineage kinase-like protein (MLKL), particularly following stimulation with tumor necrosis factor (TNF) in the presence of Smac mimetics and pan-caspase inhibitors. While it was known that MLKL phosphorylation and polymerization are essential for necroptosis execution, the precise role of these polymers and their downstream effects on subcellular organelles remained unclear. Specifically, the mechanism linking MLKL activity to the disruption of intracellular membranes and cell death had not been fully resolved.

Key Innovation from the Reference Study

The study by Liu et al. (Cell Death & Differentiation, 2024) provides direct mechanistic evidence that MLKL polymerization at lysosomal membranes is a pivotal event triggering lysosomal membrane permeabilization (LMP). This LMP precedes plasma membrane rupture and promotes the release of mature lysosomal proteases, notably cathepsin B (CTSB), into the cytosol. The released cathepsins then cleave essential cellular proteins, thereby executing necroptosis. Importantly, the study demonstrates that inhibition or knockdown of cathepsin B significantly protects cells from necroptosis, establishing CTSB as a critical effector downstream of MLKL-mediated lysosomal disruption.

Methods and Experimental Design Insights

Liu et al. employed a combination of live cell imaging, biochemical assays, and genetic/chemical perturbations to dissect the necroptotic pathway:

• Human colon cancer HT-29 cells were induced to undergo necroptosis using TNF, Smac mimetic, and the pan-caspase inhibitor Z-VAD-FMK (referred to as T/S/Z treatment).
• Lysosomes were pre-labeled with 10 kDa fluorescent dextran beads or LysoTracker Red to monitor lysosomal integrity in real-time.
• Plasma membrane rupture was tracked using Sytox Green, a membrane-impermeable DNA dye.
• The temporal relationship between LMP and plasma membrane rupture was established by dual imaging.
• To assess the functional role of cathepsins, chemical inhibitors (including selective cathepsin B inhibitors) and siRNA-mediated knockdown approaches were used.
• The polymerization status and subcellular localization of MLKL were determined using biochemical fractionation and immunofluorescence microscopy.

This experimental framework allowed for high-resolution dissection of the sequence of necroptotic events and the identification of critical molecular effectors.

Core Findings and Why They Matter

The reference study produced several key findings:

• MLKL polymerizes on lysosomal membranes: Upon necroptosis induction, activated MLKL translocates and polymerizes at the lysosomal membrane surface.
• Lysosomal membrane permeabilization is an early event: LMP, visualized by the leakage of fluorescent dextran and LysoTracker signal, consistently occurred prior to plasma membrane rupture (study).
• Release of lysosomal contents into the cytosol: LMP resulted in the rapid dispersal of lysosomal enzymes, including cathepsin B, into the cytosol, where they can act on a broad range of substrates.
• Cathepsin B is a key executioner: Both pharmacological inhibition and genetic depletion of cathepsin B significantly reduced necroptotic cell death, supporting a causal role for this protease in necroptosis execution.
• Polymerization of the MLKL N-terminal domain is sufficient: Induced polymerization of the MLKL NTD alone was able to trigger LMP, cathepsin B release, and cell death, affirming the sufficiency of this mechanism.

These findings clarify that lysosomal rupture and cathepsin B release are not secondary effects of plasma membrane damage, but are critical, early determinants of necroptosis in human cells. The work underscores the concept that regulated necrotic cell death is orchestrated by a cascade of organellar and enzymatic events, with cathepsin B serving as a principal effector following MLKL-driven lysosomal disruption.

Comparison with Existing Internal Articles

Several recent articles have highlighted the utility of selective cathepsin B inhibitors, such as CA-074 Me, in dissecting mechanisms of cell death and lysosomal enzyme function:

• "CA-074 Me: Precision Cathepsin B Inhibitor for Cell Death Research" describes the value of CA-074 Me in distinguishing cathepsin B-dependent processes within apoptosis and necroptosis workflows, echoing the findings of Liu et al. that cathepsin B is a pivotal mediator of lysosomal cell death.
• "Translating Cathepsin B Inhibition: CA-074 Me in Necroptosis Research" reviews how the latest mechanistic advances—such as those involving MLKL and lysosomal permeabilization—have been leveraged to optimize experimental models of regulated necrosis, aligning with the reference study’s focus on lysosomal pathways and cell death execution.
• "Optimizing Apoptosis Assays Using CA-074 Me (Cathepsin B inhibitor)" provides practical guidance for deploying selective cathepsin inhibitors in cell death and lysosomal pathway assays, reinforcing the translational relevance of targeting CTSB in regulated cell death research.

Collectively, these articles support the practical application of cathepsin B inhibitors for mechanistic dissection and workflow optimization in both basic and applied necroptosis research.

Limitations and Transferability

While the study by Liu et al. robustly demonstrates the sequence of MLKL-mediated lysosomal permeabilization and cathepsin B-dependent necroptosis in HT-29 cells, several limitations should be considered:

• Cell type specificity: The majority of experiments were conducted in human colon cancer cells; extrapolation to primary cells or in vivo systems should be performed with caution.
• Protease redundancy: Although cathepsin B emerged as a dominant effector, other lysosomal proteases (e.g., cathepsin L, cathepsin D) may also contribute under specific conditions, as highlighted by the observed partial inhibition of cathepsin L by CA-074 Me under reducing conditions in biochemical assays (product information).
• Temporal resolution: The precise molecular triggers for MLKL translocation to lysosomes, and the potential involvement of other organelles or upstream regulators, remain to be fully elucidated.
• Transferability to disease models: While the mechanistic insights are compelling, further work is needed to establish the relevance of MLKL-LMP-CTSB axis in complex disease settings such as TNF-α-induced liver injury or chronic inflammation.

Protocol Parameters

• Necroptosis induction: Treat cells with TNF (10–20 ng/mL), Smac mimetic (1–2 µM), and Z-VAD-FMK (20–50 µM) for 2–6 hours, adjusting concentrations for cell type sensitivity.
• Lysosomal loading: Incubate cells with 10 kDa Alexa Fluor-labeled dextran (0.5–1 mg/mL) overnight, followed by thorough washing to remove extracellular dye.
• Cathepsin B inhibition: Pre-treat cells with a selective cathepsin B inhibitor (e.g., CA-074 Me) at 5–20 µM for 1 hour prior to necroptosis induction; higher concentrations or pre-incubation times may be required in primary or resistant cell types.
• Live cell imaging: Use LysoTracker Red (50–100 nM) and Sytox Green (500 nM–1 µM) to visualize lysosomal integrity and plasma membrane rupture, respectively, capturing images at 5–10 minute intervals.
• Genetic knockdown: Employ siRNA targeting MLKL or CTSB (50–100 nM) transfected 48–72 hours before stimulation to validate the specificity of observed effects.

Research Support Resources

For researchers aiming to experimentally validate or extend these findings, CA-074 Me (Cathepsin B inhibitor, SKU A8239) offers a potent, membrane-permeable tool to selectively inhibit cathepsin B activity in both cell-based and biochemical assays. This reagent can be used to dissect the contribution of cathepsin B to lysosomal membrane permeabilization, apoptosis, and necroptosis workflows, and is compatible with inflammation and TNF-α-induced liver injury models. For detailed application scenarios and comparative insights, APExBIO provides comprehensive product specifications and guidance for optimizing cell death and lysosomal pathway assays.